N-[(3,5-dibromopyridin-2-yl)carbamothioyl]benzamide | 31430-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(3,5-dibromopyridin-2-yl)carbamothioyl]benzamide
• 英文别名: 1-benzoyl-3-(3,5-dibromo-pyridin-2-yl)-thiourea；N-(3,5-dibromopyridin-2-ylaminothiocarbonyl)benzamide
• CAS: 31430-58-7
• 化学式: C₁₃H₉Br₂N₃OS
• 分子量: 415.108
• InChiKey: FKQZCORYQDAYHQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.851±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[(3,5-dibromopyridin-2-yl)carbamothioyl]benzamide 在 水 、 sodium hydride 、 sodium hydroxide 、 copper dichloride 、 亚硝酸异戊酯 作用下， 以 N-甲基吡咯烷酮 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.92h， 生成 6-bromo-2-chlorothiazolo[4,5-b]pyridine
  参考文献：
  名称：

  ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

  摘要：

  公开号：

  EP2351744B1
• 作为产物：
  描述：

  2-氨基-3,5-二溴吡啶 、 苯甲酰基异硫氰酸酯 以 丙酮 为溶剂， 反应 18.0h， 以83%的产率得到N-[(3,5-dibromopyridin-2-yl)carbamothioyl]benzamide
  参考文献：
  名称：

  ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

  摘要：

  公开号：

  EP2351744B1

文献信息

• ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE
  申请人：Masuda Koji

  公开号：US20110251386A1

  公开（公告）日：2011-10-13

  Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: —C(R 1 R 2 )—C(═O)—NR 3 R 4 and a group represented by the formula: —R 5 , a broken line represents the presence or the absence of a bond, Z is —NR 6 —, ═N—, —O—, or —S—, R 6 is halogen, substituted or unsubstituted alkyl or the like, R 1 and R 2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is hydrogen, substituted or unsubstituted alkyl or the like, R 3 and R 4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R 5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

  公开了一种作为内皮酯酶抑制剂有用的化合物。一种具有内皮酯酶抑制活性的药物组合物，包括下式所示的化合物：其药学上可接受的盐或其溶剂合物，其中，环A是含氮杂环，环A可以被除了由下式表示的基团：—C(R1R2)—C(═O)—NR3R4和由下式表示的基团：—R5以外的基团取代，其中，一条虚线表示键的存在或不存在，Z为—NR6—，═N—，—O—或—S—，R6为卤素，取代或未取代的烷基或类似物，R1和R2各自独立地为氢、卤素、羟基、氰基、硝基、羧基或取代或未取代的烷基，R3为氢或取代或未取代的烷基，R4为氢、取代或未取代的烷基或类似物，R3和R4与它们所连接的相邻氮原子一起可以形成取代或未取代的环，R5为氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基或类似物。
• NOVEL BICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3372601A1

  公开（公告）日：2018-09-12

  Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

  本发明提供了一种对 KAT-II 具有卓越抑制作用的新型化合物、其生产方法、其用途以及含有上述化合物的药物组合物等。 一种由式（I）代表的化合物或其药理学上可接受的盐。 其中各符号如说明书中所定义。
• Bicyclic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10793582B2

  公开（公告）日：2020-10-06

  Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

  本发明提供了一种对 KAT-II 具有卓越抑制作用的新型化合物、其生产方法、其用途以及含有上述化合物的药物组合物等。 一种由式（I）代表的化合物或其药理学上可接受的盐。 其中各符号如说明书中所定义。
• 并环含氮化合物、其中间体、制备方法和应用
  申请人：杭州圣域生物医药科技有限公司

  公开号：CN117946138A

  公开（公告）日：2024-04-30

  本发明公开了一种并环含氮化合物、其中间体、制备方法和应用。本发明提供了一种如式I所示的化合物、其药学上可接受的盐或同位素化合物。本发明的化合物的ATPase活性和对蛋白的抑制效果较现有技术有较大改善。#imgabs0#
• Pharmaceutical Compositions For and Methods of Inhibiting Hcv
  申请人：Huang Mingjun

  公开号：US20080207760A1

  公开（公告）日：2008-08-28

  The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.